Bavarian Nordic shares surge on order for monkeypox vaccine amid Europe outbreaks; one case in the U.S
Shares of a Danish pharmaceutical group surged on Thursday after the company received an order for its vaccine to treat monkeypox, a rare disease that has cropped up recently across a handful of European countries. The relatively rare virus has been detected in Portugal, the U. Monkeypox has largely been seen in Africa, triggered by infections from rodent and small-animal bites.
The illness typically starts off with flulike symptoms and swelling lymph nodes, followed by a rash on the face and body, and usually takes two to four weeks to resolve. The fatality rate is roughly 0% to 10%, and slightly higher among children, WHO said. Bavarian Nordic’s smallpox vaccine has been approved in the U.
“While the full circumstances around the current monkeypox cases in Europe remain to be elucidated, the speed of which these have evolved, combined with the potential for infections beyond the initial case going undetected, calls for a rapid and coordinated approach by the health authorities, and we are pleased to assist in this emergency situation,” said Paul Chaplin, CEO of Bavarian Nordic. “Infection control has been a high priority for societies during COVID-19, and this situation is an unfortunate reminder that we cannot let our guard down but must continue to build and strengthen our infectious-disease preparedness to keep the world open,” he said.
Read full article at MarketWatch